VectivBio Holding AG (VECT) – Press Releases
-
Alentis Therapeutics Appoints Luca Santarelli as Chairperson
-
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
-
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
-
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
-
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
-
VectivBio Publishes Invitation to the Annual General Meeting
-
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
-
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
-
VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
-
VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
-
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
-
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
-
VectivBio Announces Results of Extraordinary General Meeting
-
VectivBio Announces Results of Extraordinary General Meeting
-
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
-
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
-
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
-
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
-
VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
-
VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
-
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
-
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
-
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
-
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
-
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Cont
-
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Cont
-
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
-
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
-
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
-
VectivBio Announces Closing of $54 Million Aggregate Financing
-
VectivBio Announces Closing of $54 Million Aggregate Financing
-
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
-
VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares
-
VectivBio Announces Launch of Public Offering of Ordinary Shares
-
VectivBio Announces Launch of Public Offering of Ordinary Shares
-
VectivBio Publishes Invitation to the Annual General Meeting
-
VectivBio Publishes Invitation to the Annual General Meeting
-
VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease
-
VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease
-
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
-
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
-
VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
-
VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications
-
VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
-
VectivBio Reports Full Year 2021 Financial Results and Provides Business Update
-
VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
-
VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
-
VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of P
-
VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of P
-
VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation
Back to VECT Stock Lookup
